DataSheet_1_MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants.docx

Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and moderate infections. These therapeutics target the spike protein of SARS-CoV-2; however, emerging mutations in this protein reduce their efficiency. In this study, we developed a universal SARS-CoV-2 neutralizing antibody. We generated a humanized monoclonal antibody, MG1141A, against the receptor-binding domain of the spike protein through traditional mouse immunization. We confirmed that MG1141A could effectively neutralize live viruses, with an EC50 of 92 pM, and that it exhibited effective Fc-mediated functions. Additionally, it retained its neutralizing activity against the alpha (UK), beta (South Africa), and gamma (Brazil) variants of SARS-CoV-2. Taken together, our study contributes to the development of a novel antibody therapeutic approach, which can effectively combat emerging SARS-CoV-2 mutations.

自2019年新型冠状病毒病暴发以来，科研人员已开发出多款抗体治疗药物，用于治疗严重急性呼吸综合征冠状病毒2（severe acute respiratory syndrome coronavirus 2, SARS-CoV-2）感染。此类抗体治疗药物可有效中和病毒，减轻轻中度感染患者的住院负担，但其靶点为SARS-CoV-2的刺突蛋白（spike protein），该蛋白出现的新发突变会降低药物的治疗效力。本研究开发了一款广谱SARS-CoV-2中和抗体：通过传统小鼠免疫法，我们制备了靶向刺突蛋白受体结合域（receptor-binding domain）的人源化单克隆抗体（humanized monoclonal antibody）MG1141A。实验证实，MG1141A可有效中和活病毒，半最大效应浓度（EC50）为92 pM，且具备良好的Fc段介导功能。此外，该抗体对SARS-CoV-2的阿尔法（英国）、贝塔（南非）及伽马（巴西）变异株仍保留中和活性。综上，本研究为新型抗体治疗策略的开发提供了重要支撑，可有效应对不断出现的SARS-CoV-2突变株。